October 6, 2025
The Alliance for Clinical Trials in Oncology has launched the ASPIRE trial—a large-scale, Phase III clinical study investigating whether adding chemotherapy to current standard treatments can extend survival for men living with advanced prostate cancer.
The ASPIRE trial (Alliance A032302) is enrolling 1,200 participants across the United States with metastatic castrate-sensitive prostat
September 30, 2025
A groundbreaking new study from the Alliance for Clinical Trials in Oncology aims to test whether digital tools and chatbot technology can help young adult cancer survivors get the genetic counseling they need to better understand future health risks to themselves and family members.
Led by Alliance Study Chair Angela Bradbury, MD, Professor of Medicine in the Division of
September 29, 2025
Alliance A032302: Docetaxel addition in metastatic castrate-sensitive prostate cancer (ASPIRE)
Deepak Kilari, MD, of Medical College of Wisconsin, leads this phase III trial that compares the effect of adding docetaxel to hormonal therapy and apalutamide versus hormonal therapy and apalutamide alone in treating patients with prostate cancer that has spread from where i
